Novartis Lescol XL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Extended-release 80 mg tablet formulation of fluvastatin produced up to a 38% median decrease in low-density lipoprotein cholesterol in patients with dyslipidemia compared to Lescol 40 mg in Phase III clinical trials, the company said, announcing the Oct. 6 approval of the new tablet. "A 25% median decrease in triglycerides and a 13% mean increase in high-density lipoprotein cholesterol in patients with primary mixed dyslipidemia (Fredrickson Type IIb)" compared to Lescol 40 mg was also seen in the trials, the company reported. The NDA for the extended-release formulation was submitted Dec. 8, 199
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.